title: LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene.
abstract: We present here the clinical, molecular and biochemical findings from 238 limb-girdle muscular dystrophy type 2A (LGMD2A) patients, representing approximately 50% (238 out of 484) of the suspected calpainopathy cases referred for the molecular study of the calpain 3 (CAPN3) gene. The mean age at onset of LGMD2A patients was approximately 14 years, and the first symptoms occurred between 6 and 18 years of age in 71% of patients. The mean age at which the patients became wheelchair bound was 32.2 years, with 84% requiring the use of a wheelchair between the age of 21 and 40 years. There was no correlation between the age at onset and the time at which the patient became wheelchair bound, nor between the sex of the patient and the risk of becoming wheelchair bound. Of the cases where the CAPN3 gene was not affected, approximately 20% were diagnosed as LGMD2I muscular dystrophy, while facioscapulohumeral muscular dystrophy (FSHD) was uncommon in this sample. We identified 105 different mutations in the CAPN3 gene of which 50 have not been described previously. These were distributed throughout the coding region of the gene, although some exons remained free of mutations. The most frequent mutation was 2362AG-->TCATCT (exon 22), which was present in 30.7% of the chromosomes analysed (146 chromosomes). Other recurrent mutations described were N50S, 550DeltaA, G222R, IVS6-1G-->A, A483D, IVS17+1G-->T, 2069-2070DeltaAC, R748Q and R748X, each of which was found in >5 chromosomes. The type of mutation in the CAPN3 gene does not appear to be a risk factor for becoming dependent on a wheelchair at a determined age. However, in the cases with two null mutations, there were significantly fewer patients that were able to walk than in the group of patients with at least one missense mutation. Despite the fact that the results of phenotyping and western blot might be biased due to multiple referral centres, producing a diagnosis on the basis of the classical phenotype is neither sufficiently sensitive (86.7%) nor specific (69.3%), although western blot proved to be even less sensitive (52.5%) yet more specific (87.8%). In this case LGMD2I was a relevant cause of false-positive diagnoses. Considering both the clinical phenotype and the biochemical information together, the probability of correctly diagnosing a calpainopathy is very high (90.8%). However, if one of the analyses is lacking, the probability varies from 78.3 to 73.7% depending on the information available. When both tests are negative, the probability that the sample comes from a patient with LGMD2A was 12.2%.
authors.affiliation: Unidad Experimental, Hospital Donostia, San Sebastián, Basque Country, Spain. uniexpe2@chdo.osakidetza.net
authors.forename: A
authors.initials: A
authors.lastname: Sáenz
authors.forename: F
authors.initials: F
authors.lastname: Leturcq
authors.forename: A M
authors.initials: AM
authors.lastname: Cobo
authors.forename: J J
authors.initials: JJ
authors.lastname: Poza
authors.forename: X
authors.initials: X
authors.lastname: Ferrer
authors.forename: D
authors.initials: D
authors.lastname: Otaegui
authors.forename: P
authors.initials: P
authors.lastname: Camaño
authors.forename: M
authors.initials: M
authors.lastname: Urtasun
authors.forename: J
authors.initials: J
authors.lastname: Vílchez
authors.forename: E
authors.initials: E
authors.lastname: Gutiérrez-Rivas
authors.forename: J
authors.initials: J
authors.lastname: Emparanza
authors.forename: L
authors.initials: L
authors.lastname: Merlini
authors.forename: C
authors.initials: C
authors.lastname: Paisán
authors.forename: M
authors.initials: M
authors.lastname: Goicoechea
authors.forename: L
authors.initials: L
authors.lastname: Blázquez
authors.forename: B
authors.initials: B
authors.lastname: Eymard
authors.forename: H
authors.initials: H
authors.lastname: Lochmuller
authors.forename: M
authors.initials: M
authors.lastname: Walter
authors.forename: C
authors.initials: C
authors.lastname: Bonnemann
authors.forename: D
authors.initials: D
authors.lastname: Figarella-Branger
authors.forename: J C
authors.initials: JC
authors.lastname: Kaplan
authors.forename: J A
authors.initials: JA
authors.lastname: Urtizberea
authors.forename: J F
authors.initials: JF
authors.lastname: Martí-Massó
authors.forename: A
authors.initials: A
authors.lastname: López de Munain
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D001499:Bayes Theorem; D015153:Blotting, Western; D002154:Calpain / Q000235:genetics*; D002648:Child; D004252:DNA Mutational Analysis / Q000379:methods; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006801:Humans; D007527:Isoenzymes / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000235:genetics*; D049288:Muscular Dystrophies, Limb-Girdle / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics*; D020125:Mutation, Missense; D010641:Phenotype; D012189:Retrospective Studies
chemical_list: D007527:Isoenzymes; D009124:Muscle Proteins; C105884:CAPN3 protein, human; D002154:Calpain